INTRODUCTION

Melanoma is among the most lethal forms of skin cancer, accounting for the vast majority of skin cancer deaths in the United States each year (Miller et al., 2019). Over the past decade, significant advances in understanding the molecular basis for melanoma onset and progression have allowed for the development of novel therapies, which have dramatically improved patient outcomes, including targeted BRAF inhibitors (BRAFis), MAPK/extracellular signal–regulated kinase inhibitors (MEKis), and immunotherapies. Although targeted therapies elicit rapid antitumor responses in the majority of patients with BRAF-mutant melanoma, nearly all patients develop drug resistance and disease progression within a year of treatment initiation (Sullivan and Flaherty, 2013). Immunotherapies have also demonstrated significant responses; however, patients frequently show intrinsic or acquired resistance to such therapies. Accumulating data suggest that epigenetic alterations are involved in melanoma development, progression, and tumor cell plasticity; moreover, epigenetic changes are implicated as critical mediators of melanoma therapeutic resistance. In this review, we provide an overview of epigenetic alterations in melanoma progression and resistance to targeted therapies and immune checkpoint inhibition. We further review the current state of epigenetic therapies in preclinical and clinical settings for melanoma and share promising future applications of such agents.

EPIGENETICS AND CANCER

Epigenetics refers to reversible changes of gene expression, which are heritable and not associated with DNA sequence changes. The most widely studied epigenetic mechanisms include DNA methylation, histone tail modifications, and regulation through noncoding RNAs. To coordinate biological processes and regulate gene expression, the epigenome interacts with various cellular elements, including noncoding RNAs and transcription factors, and is widely viewed as a biological rheostat responding to cell signaling pathways and extracellular stimuli to rapidly influence cell functions.

Although cancer is primarily a genetic disease, mutational events occur at too low a frequency to account for the efficient malignant transformation and therapeutic resistance observed in most malignancies that lack defects in DNA repair (Shen and Laird, 2013). Epigenetic changes were first implicated in tumorigenesis over 40 years ago with the observation that DNA methyltransferase (DNMT) activity is implicated in tumorigenesis over 40 years ago with the observation that DNA methyltransferase (DNMT) activity is associated with malignant transformation (Holliday, 1979). Today, the epigenome is known to allow genetically identical cells to cycle between diverse, stable phenotypes and acquire oncogenic traits (Shen and Laird, 2013) and therapeutic resistance (Boumahdi and de Sauvage, 2020; Strub et al., 2020) in melanoma and other cancers (Feinberg and Tycko, 2004; Moran et al., 2018).
**DNA modifications**

DNMT enzymes catalyze the transfer of a methyl group to a cytosine residue on a CpG dinucleotide, which allows for binding of methyl-CpG-binding domain proteins and transcriptional silencing (Figure 1a). In the mammalian genome, CpG dinucleotides occur in long repetitive sequences or in CpG islands associated with gene promoters (Smith et al., 2010), and both DNA hypermethylation and hypomethylation have been implicated in oncogenesis (Rodríguez-Paredes and Esteller, 2011).

DNA hypomethylation was the first epigenetic mark to be associated with human cancers (Feinberg and Vogelstein, 1983). Global DNA hypomethylation may result in genomic instability (Rodríguez-Paredes and Esteller, 2011) and has been observed in virtually all cancers, including melanoma (Chatterjee et al., 2018; Ehrlich, 2009) where it is associated with increased immunotherapeutic resistance in patients (Jung et al., 2019) and promotion of cell proliferation, angiogenesis, metastasis, and poor patient outcomes (Van Tongelen et al., 2017; Vizoso et al., 2015; Wang et al., 2016).

DNA hypermethylation in melanoma promotes transcriptional silencing of over 70 genes involved in tumorigenesis (Schinke et al., 2010; Sigalotti et al., 2010), including tumor suppressors PTEN, RASSF1A, and p16INK4a/14ARF (Jones and Baylin, 2002; Micevic et al., 2017), as well as genes associated with DNA repair (Moran et al., 2018).

**Histone modifications**

The nucleosome is the basic functional unit of chromatin and consists of DNA wrapped around a complex of histones (Dawson and Kouzarides, 2012). Histones may be modified by covalent post-translational modifications (PTMs), including methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation. These PTMs may affect chromatin structure or recruit histone modifiers leading to altered gene transcription in cancers (Arrowsmith et al., 2012). Lysine and arginine residues on histones may be monomethylated, dimethylated, or trimethylated with specific methyl marks signaling transcriptional activation or repression. For example, trimethylation of lysine 9 and 27 of histone H3 (H3K9me3 and H3K27me3) is associated with transcriptional silencing, whereas H3K4me3 is associated with transcriptional activation (Arrowsmith et al., 2012). H3K4me2 and H3K27me3 marks are increased in melanomas and may serve as biomarkers for cancer cells with stem cell–like properties (Kampilafkos et al., 2015).

Enhancer of zeste homolog 2 (EZH2) (Figure 1b), a histone methyltransferase that is the core subunit of PRC2, promotes...
tumor growth across a variety of cancer types (Bachmann et al., 2006; Mahmoud et al., 2016). EZH2 promotes tri- 
methylation of histone H3 lysine 27 (H3K27me3), resulting in transcriptional silencing (Mahmoud et al., 2016) of genes, 
including tumor suppressors, HLA classes I and II, and other components of the immune system (Emran et al., 2019). EZH2 
also interacts with DNMTs, inducing hypermethylation of promoter Cpg islands (Moran et al., 2018). EZH2 shares 
several upstream signaling pathways with DNMTs, including BRAFV600E (Emran et al., 2019), and EZH2 activity has been 
associated with drug resistance in melanomas and prostate cancers (Boumahdi and de Sauvage, 2020; Zingg et al., 2017).

Enhanced activity of LSD1 (Figure 1c and d), the first histone demethylase to be identified (Shi et al., 2004), has been 
observed in several cancers, including melanoma (Maiques-Diaz and Somerville, 2016; Yu et al., 2018). LSD1 is a core 
component of the CoREST repressor complex (Laugesen and Helin, 2014) and can demethylate histone and nonhistone 
substrates, including the tumor suppressor and transcriptional coactivator p53 (Huang et al., 2007). When associated with 
the histone deacetylases (HDACs) (HDAC1/2) in the CoREST complex, LSD1 primarily demethylates lysine 4 of histone H3, 
leading to transcriptional silencing (Laugesen and Helin, 2014; Shi et al., 2004). LSD1 also demethylates H3K9me3 
in melanoma, promoting tumor cell growth (Yu et al., 2018). Inhibition of LSD1 activity enhances tumor immunogenicity 
and T-cell infiltration in melanoma, which resemits checkpoint blockade–refractory tumors to anti–PD-1 therapy (Sheng et al., 2018), whereas inhibition of the CoREST complex 
inhibits melanoma cell growth and resistance to targeted therapies (Kalin et al., 2018; Wu et al., 2020).

Histone acetylation largely determines chromatin states and subsequent transcriptional activity (Boden et al., 2006). His-
tone lysine acetylation promotes transcriptionally active chroma-
atin, whereas deacetylation promotes chromatin compaction (Boden et al., 2006); HDACs catalyze the removal of acetyl 
groups from lysine residues of both histone and nonhistone proteins; are associated with gene silencing (Boden et al., 
2006); and regulate tumor cellular proliferation, differentiation, 
and immunogenicity (Hornig et al., 2016) (Figure 1e). Four 
main classes of HDACs have been identified with class I (zinc-
dependent sirtuins [SIRTs]) and class III (NAD+-dependent 
SIRTs) HDACs as being of particular interest in oncogenesis 
(Garcia-Peterson et al., 2017; Weichert, 2009). Expression of 
class I HDACs, including HDAC1, 2, and 3, has been implicated 
in the development of melanoma (Rothhammer and Bosserhoff, 
2007). SIRT1 inhibition resemites BRAF-mutant melanomas 
to BRAFi therapy (Ohanna et al., 2014), whereas inhibition of 
SIRT2 promotes MAPK inhibitor resistance in BRAF-mutant 
melanoma (Bajpe et al., 2015). Targeting SIRTs in cancer is 
complex because many have been found to possess tumor-
suppresser and tumor-promoter functions (Garcia-Peterson 
et al., 2017); however, targeting of HDACs largely promotes 
anticancer effects (Hornig et al., 2016).

Histone acetylation, catalyzed by histone acetyl-
transferases (HATs), promotes open chromatin states and 
increased gene transcription (Arrowsmith et al., 2012), which 
may be associated with cancer (Portela and Esteller, 2010) 
(Figure 1f). The p300/CPB HAT is of particular interest in 
cancer because it may acetylate lysine residues on all four 
histones and regulate numerous cancer-associated pathways, 
including TGF-β, p53, and pRb (Iyer et al., 2004). Inhibition of 
p300 HAT in melanoma inhibits the expression of cell cycle regulatory genes, resulting in cellular senescence (Bandyopadhyay et al., 2002; Kim et al., 2019).

**EPIGENETICS AND THERAPEUTIC RESISTANCE IN MALIGNANT MELANOMA**

As the role of the epigenome in the biology of cancer and its 
specific functions in the emergence of drug tolerance and 
resistance in melanoma becomes elucidated, the develop-
ment of novel treatments targeting the epigenome is rapidly 
expanding and may provide promise for more durable ther-
apeutic responses. Although the investigations of epigenetic 
agents as monotherapies are ongoing, no single epigenetic 
therapeutic agent has proven effective for melanoma to date; 
however, emerging evidence suggests that their greatest 
benefits may lie in use as adjunctive therapies with other 
classes of drugs (Table 1). Given the inherent and acquired 
resistance to targeted and immunotherapies seen in mel-
oma, the prospect of combining epigenetic therapies with 
such established treatments to overcome this resistance is 
particularly promising. Below, we review the current status 
of various classes of epigenetic agents and how they are being 
developed in melanoma.

**Combination epigenetic therapies for melanoma**

In BRAF-mutant melanomas, reactivation of the MAPK 
pathway is a crucial mechanism in the development of 
resistance to targeted therapies (Long et al., 2014), which 
is largely linked to changes in gene expression and transcrip-
tional programs, as opposed to gene mutations (Arozarena 
and Wellbrock, 2019). As such, epigenetic alterations have 
emerged as key players in the ability of melanoma cells to 
achieve resistance to BRAFi/MEKi therapies and are being 
evaluated as targets to overcome resistance. In addition, 
epigenetic alterations have been found to induce changes in 
both cancer and immune cells that enhance antitumor 
cellular responses, suggesting the utility of epigenetic agents 
in combination with immunotherapies (Chiappinelli et al., 
2016; Héninger et al., 2015). Indeed, preclinical work sug-
ests the benefit of combining immunotherapies alongside 
numerous classes of epigenetic drugs, and combination 
treatment protocols exploring the use of epigenetic therapies 
and immune modulators are actively being investigated in 
clinical trials (Table 2).

**DNMT inhibitors.** DNMT inhibitors (DNMTis), such as 5-
aza-2′-deoxycytidine (decitabine), were 
first synthesized in the 1960s and have been explored in 
clinical trials for a number of different malignancies, making 
them among the longest studied of epigenetic therapies 
(Christman, 2002; Sorm et al., 1964). These agents are cyti-
dine analogs that block the catalytic activity of DNMTs, thus 
inhibiting DNA synthesis (Figure 1a) (Ahn et al., 2017). 
Perhaps the most promising potential application of DNMTis 
in the treatment of malignant melanoma is in combination

---

1 Wu M, Hanly A, Gibson F, Kuang K, Kalin J, Nocco S, et al. The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma. bioRxiv 2020.
with immunotherapy. In previous studies, the treatment of melanoma cell lines with decitabine resulted in improved recognition of melanoma cells by gp100-specific cytotoxic T cells through the upregulation of HLA class I antigens and ICAM-1 (Fonsatti et al., 2007). In addition, treatment of a murine melanoma model with low-dose decitabine led to increased macrophage effector and dendritic cell activation and decreased myeloid suppressor activity (Triozzi et al., 2012). Studies by Chiappinelli et al. (2015) showed that DNMTi therapies activated the viral defense response through cytoplasmic dsRNA sensing, thus potentiating the effects of anti-CTLA4 immune

### Table 1. Combination Treatment with Selected Epigenetic Therapies and Other Agents

| Class of Combination Agent | Examples | Rationale | Refs |
|----------------------------|----------|-----------|------|
| Epigenetic therapy: DNMT inhibitors | BRAF inhibitors | Vemurafenib + decitabine | DNMT1 is upregulated by MAPK pathway and causes hypermethylation of BRAFV600E-mutant genes | Hou et al., 2012; Zakharia et al., 2017 |
| | Anti–PD-1 antibodies | Azacitidine + pembrolizumab (NCT02816021) | DNMT inhibition promotes PD-L1 expression | Chatterjee et al., 2018; Micevic et al., 2017 |
| | Anti–CTLA-4 antibodies | Azacitidine + anti–CTLA-4 antibodies | DNMT inhibition improves the recognition of tumor cells by T cells and upregulates viral defense response through cytoplasmic dsRNA sensing | Chiappinelli et al., 2015; Fonsatti et al., 2007; Triozzi et al., 2012 |
| Alkylating agents | Decitabine + TMZ | Downregulation of MGMT, which is the mechanism by which melanoma cells achieve TMZ resistance | Tawbi et al., 2013 |
| Epigenetic therapy: EZH2 inhibitors | BRAF inhibitors | GSK2816126 + vemurafenib | BRAF mutations increase EZH2, leading to the downregulation of tumor suppressor genes | Yu et al., 2017; Zingg et al., 2015 |
| | Anti–CTLA-4 antibodies | GSK303 + anti–CTLA-4 antibodies | EZH2 silences immunogenicity in tumor cells | Goswami et al., 2018; Zingg et al., 2017, 2015 |
| Epigenetic therapy: HDAC inhibitors | BRAF inhibitors | Panobinostat + encorafenib | HDACis reduce activity in RTK and PI3K signaling pathways | Emmons et al., 2019; Gallagher et al., 2018; Maertens et al., 2019 |
| | Anti–PD-1 antibodies | Nexturastat A + anti–PD-1 antibodies | HDACis increase the expression of PD-L1, enhancing T-cell activity | Knox et al., 2019 |
| | LSD1 inhibitors | Corin | Inhibiting the CoREST complex by cotargeting HDAC1/2 and LSD1 leads to growth inhibition | Kalin et al., 2018; Wu et al., 2020 |
| BET inhibitors | LBH598 + I-BET151 | Caspase-dependent increase in apoptosis | Heinemann et al., 2015 |

Abbreviations: DNMT, DNA methyltransferase; dsRNA, double-stranded RNA; EZH2, enhancer of zeste homolog 2; Ref, reference; HDAC, histone deacetylase; HDACi, histone deacetylase inhibitor; MGMT, O[6]-methylguanine-DNA methyltransferase; PI3K, phosphoinositide 3-kinase; TMZ, temozolomide.

### Table 2. Current Clinical Trials with Epigenetic Agents and Immunotherapies in Cutaneous Melanoma

| Drug | Target | Cancer Type | Phase | Status | NCT Number |
|------|--------|-------------|-------|--------|------------|
| Entinostat | HDAC1 PD-1 | Melanoma | II | Recruiting | NCT03765229 |
| Pembrolizumab | | | | | |
| Tinostamustine | HDAC PD-1 | Melanoma | I | Recruiting | NCT03903458 |
| Nivolumab | | | | | |
| Abexinostat | HDAC PD-1 | Advanced solid tumors | Ib | Recruiting | NCT03590054 |
| Pembrolizumab | | | | | |
| Mecetinostat | HDAC CTLA-4 PD-1 | Melanoma | Ib | Recruiting | NCT03565406 |
| Ipilimumab | | | | | |
| Nivolumab | | | | | |
| Domatinostat | HDAC PD-1 CTLA-4 | Melanoma | Ib | Not yet recruiting | NCT04133948 |
| Nivolumab | | | | | |
| Ipilimumab | | | | | |
| Panobinostat | HDAC CTLA-4 | Melanoma | I | Active, not recruiting | NCT02032810 |
| Ipilimumab | | | | | |
| Azacitidine | DNMT PD-1 | Melanoma | II | Recruiting | NCT02816021 |
| Pembrolizumab | | | | | |
| HBI-8000 | HDAC PD-1 | Melanoma, renal cell carcinoma, NSCLC | Ib/II | Recruiting | NCT02718066 |
| Nivolumab | | | | | |
| Entinostat | HDAC1 PD-1 | NSCLC, melanoma, colorectal cancer | Ib/II | Active, not recruiting | NCT02437136 |

Abbreviations: DNMT, DNA methyltransferase; HDAC, histone deacetylase; NCT, National Clinical Trial; NSCLC, non–small cell lung cancer.
checkpoint therapy, whereas others have shown (Chatterjee et al., 2018) that decitabine treatment of melanoma cells led to increased PD-L1. A phase II clinical trial is currently underway to assess the efficacy of combined immune checkpoint blockade (pembrolizumab) and azacitidine in patients with metastatic melanoma (NCT02816021).

By contrast, DNMTis have shown promise as melanoma therapies when combined with BRAFis. BRAFV600E knockdown in melanoma cells leads to a downregulation of DNMT expression, suggesting that BRAF V600E mutation promotes gene hypermethylation through the upregulation of DNMT (Hou et al., 2012). Zakharia et al. (2017) conducted a phase 1b study using combination treatment of oral vemurafenib with subcutaneous administration of the DNMTi, decitabine, in a small group of patients with metastatic melanoma and found delayed development of resistance and increased duration of treatment response in those treated with low-dose, long-term decitabine and vemurafenib, with no dose-limiting toxicities observed, and follow-up studies are underway. Other studies suggest that DNMTis may play a role in combatting resistance to standard chemotherapy regimens in melanoma, including treatment with the alkylating agent temozolomide (TMZ), to which patients develop resistance through epigenetic silencing of DNA mismatch repair genes such as MLH1 (Tawbi et al., 2013), and a phase I/II study investigating patients with metastatic melanoma who received the combination of decitabine and TMZ found improved overall survival and limited toxicities (Tawbi et al., 2013). Similarly, sequential treatment of melanoma cell lines with decitabine followed by the platinum-based chemotherapy carboplatin resulted in greater apoptotic response and decreased cellular proliferation (Budden et al., 2018).

EZH2 inhibitors. EZH2 transcriptionally represses several genes associated with immune responses, including genes that encode proteins involved in antigen presentation (major histocompatibility complex class I/II molecules) and chemokines needed to attract tumor-infiltrating lymphocytes (Tiffen et al., 2016). The upregulation of EZH2 and the resulting immunosuppressive microenvironment has been implicated as a mechanism through which melanoma cells develop resistance to immunotherapies (Tiffen et al., 2016; Zingg et al., 2017). After anti–CTLA-4 or IL-2 immunotherapy, melanoma cells increase EZH2 expression and transcriptionally silence the genes involved in tumor cell immunogenicity (Zingg et al., 2017). In addition, EZH2 inhibition has been shown to reverse acquired immune resistance and promote antitumor effects when combined with immunotherapies (Zingg et al., 2017), suggesting that a combination of EZH2 inhibitor (EZH2i) and immunotherapy may allow for overcoming resistance to immunotherapies in melanoma and other cancers (Tiffen et al., 2016; Zingg et al., 2017), and several EZH2is have entered clinical trials for nonmelanoma malignancies (Kim and Roberts, 2016).

EZH2 has been shown to promote melanoma growth and metastasis (Mahmoud et al., 2016), and EZH2 inhibition has been shown to impair melanoma growth and invasion (Zingg et al., 2015). Moreover, dual inhibition of BRAF and EZH2 showed synergies versus BRAFi treatment alone (Yu et al., 2017), and clinical trials of an EZH2i, tazemetostat, in advanced solid tumors are currently underway (NCT03217253, NCT01897571).

LSD1 inhibitors. Recent studies (Sheng et al., 2018) showed enhanced immune response to melanoma cells after ablation of LSD1, with subsequent increased expression of repetitive elements, including endogenous retroviral elements, and decreased expression of RNA-induced silencing complex components, leading to dsRNA stress and activation of the IFN-1 response. In addition, LSD1 ablation led to increased expression of PD-L1 on tumor cells and enhanced response to PD-1 blockade. A phase 1 trial of the LSD1 inhibitor SP-2577 (seclidemstat) is currently underway in patients with advanced solid tumors (NCT03895684). In addition, studies of the CoREST repressor complex in melanoma, of which LSD1 is a critical component, have shown enhanced antitumor immunity after CoREST inhibition by the small molecule, Corin (Xiong et al., 2020), whereas CoREST inhibition has also been shown to reactivate sensitivity to BRAFi in BRAFi-resistant melanomas in vitro and in vivo (Wu et al., 2020), further supporting its specific role in acquired resistance to BRAFi therapies.

HDAC inhibitors. HDAC inhibitors (HDACis) have been shown to promote immunogenicity of melanoma cells, including through enhanced antigen processing and presentation (Khan et al., 2008) and enhanced expression of PD-L1, suggesting the potential role of dual treatment with HDACis and PD-1 inhibitors (Lienaf et al., 2016; Woan et al., 2015; Woods et al., 2015), and recent studies (Knox et al., 2019) showed a shift to a hot, proinflammatory tumor microenvironment after melanoma treatment with the HDAC6 inhibitor Nexurastat A in combination with anti–PD-1 antibodies. These promising results suggest that dual treatment with HDACis and immunotherapies may have potent synergies. Clinical trials investigating combinational therapy with these two classes of drugs in melanoma are ongoing (NCT03590054, NCT03565406).

HDACis have also been shown to induce apoptosis and cell cycle arrest in melanoma cells (Pal-Bhadra et al., 2012; Venturelli et al., 2018), and BRAFi resistance is associated with increased expression of HDACs (Emmons et al., 2019). Treatment of melanoma cells with the HDACi suberic bis-hydroxamate has been shown to promote apoptosis (Zhang et al., 2004), whereas the pan-HDACi, LBH589, has been shown to induce apoptosis and G1 cell cycle arrest as well as increased immunogenicity in melanoma (Woods et al., 2013). Targeted inhibition of HDAC6 has also been shown to reduce the proliferation of melanoma cells and induced G1 arrest, without affecting apoptosis (Woan et al., 2015), whereas treatment of melanoma cells with the HDAC6 inhibitor ACY 1215 (ricolinostat) was shown to induce apoptosis and G0/G1 cell cycle arrest (Wang et al., 2018a).

With regard to melanoma resistance to BRAFis, HDAC8 was shown to contribute to the development of a drug-resistant phenotype in melanoma cells, whereas cotargeting of HDAC8 and BRAF in a mouse melanoma model resulted in synergistically decreased tumor growth (Emmons et al., 2018).
In addition, dual treatment of melanoma cells with panobinostat and the BRAFi, encorafenib, led to a synergistic reduction in RTK and phosphoinositide 3-kinase signaling in a subset of melanoma cell lines (Gallagher et al., 2018), whereas targeted inhibition of HDAC3 with entinostat enhanced the efficacy of BRAF/MEKis in BRAF-mutant melanomas (Maertens et al., 2019).

A major concern for the use of HDACi therapies has been their relative lack of selectivity and narrow therapeutic window. This limitation appears to have been overcome with the recent development of a novel specific inhibitor of the CoREST repressor complex, Corin (Figure 2), which showed dual-warhead activity versus LSD1 and HDAC1/2 (Kalin et al., 2018) and inhibits melanoma cell growth across a number of melanoma cell lines without significant effects on normal human melanocytes. Furthermore, treatment of BRAFi-resistant melanoma cells with Corin restored sensitivity of these tumor cells to treatment with BRAFi, suggesting that CoREST activity is a critical mediator of acquired resistance to BRAFi therapy in melanoma (Wu et al., 2020).

HATs. Following the revelation that p300/CBP inhibition resulted in decreased melanoma proliferation (Bandyopadhyay et al., 2002), significant efforts were made to develop inhibitors of p300/CBP HAT activity (Lasko et al., 2017; Yan et al., 2013). Recently, a potent and selective inhibitor of p300/CBP, A485, has been shown to decrease melanoma cell proliferation and promote cellular senescence in a MITF-dependent fashion (Kim et al., 2019; Wang et al., 2018b). Of note, recent studies identified EP300 amplifications in over 16% of acral melanomas, suggesting a potential area of therapeutic focus for these compounds (Yeh et al., 2019).

CONCLUSION AND PERSPECTIVES
Despite the monumental advances in the treatment of melanoma over the past decade, the 5-year survival rate for the advanced disease remains low (Enninga et al., 2017). Investigations into the role of epigenetic influences in melanoma have increased dramatically in recent years, leading to important discoveries that have made us rethink the role of genetic versus of nongenetic alterations in cancer and their significance as therapeutic targets. Epigenetic alterations are becoming increasingly recognized as key mechanisms by which melanoma cells evade and develop resistance to treatment with targeted and immunotherapies and are therefore widely acknowledged as crucial targets in melanoma therapy. Inhibitors of DNMTs, EZH2, LSD1, HDACs, and HATs have shown antimelanoma effects both in vitro and in vivo, particularly when combined with BRAFi or immunomodulators; however, concerns regarding off-target effects of epigenetic therapies have significantly limited their utility in the clinic. The significant potential of targeted dual-acting epigenetic therapies to generate precise and effective responses at specific epigenetic modifying complexes while minimizing off-target effects should not be underestimated, and further research to optimize such therapies is of great importance for the field. Although there are currently no Food Drug and Administration–approved epigenetic therapies for melanoma, future studies will define the utility of novel potent and specific epigenetic therapies either as single or combination agents in melanoma, which are poised to revolutionize our approach to the management of patients with advanced disease.

Epigenetic alterations represent the major mechanisms of resistance for both targeted and immunotherapies in melanoma; however, combination therapies have proved ineffective in bypassing this major therapeutic hurdle, largely owing to significant toxicities and a limited therapeutic window. Further development and exploration of novel compounds that target the epigenome are essential to developing more effective treatments in melanoma; we propose that such novel therapies must be developed in a more directed manner to allow for specific inhibition of epigenetic complexes through strategic targeting of individual epigenetic complexes and that dual-action therapeutic agents will allow for significant advances in accomplishing these goals while minimizing toxicities. In addition, current research has only scratched the surface of the myriad complexes and interactions that influence the structure of the epigenome; we therefore expect that additional investigations will further clarify the implications of such complexes in the development of melanoma and other malignancies, which will lead to improved and effective targeted epigenetic therapies.

ORCIDs
Ailish Hanly: http://orcid.org/0000-0002-2242-423X
Frederick Gibson: http://orcid.org/0000-0002-4767-5393
Sarah Nocco: http://orcid.org/0000-0002-9719-3456
Samantha Rogers: http://orcid.org/0000-0003-1876-5944
Muzhou Wu: http://orcid.org/0000-0002-6322-0313

Figure 2. A novel inhibitor of the CoREST repressor complex, Corin, shows dual-warhead activity versus LSD1 and HDAC1/2, resulting in increased sensitivity and specificity for its epigenetic target (Kalin et al., 2018). HDAC, histone deacetylase.
REFERENCES

Ahn A, Chatterjee A, Eccles MR. The slow cyclinG phenotype: a growing problem for treatment resistance in melanoma. Mol Cancer Ther 2017;16:1002–9.

Arozarena I, Wellbrock C. Phenotype plasticity as enabler of melanoma for their assistance in preparing this manuscript.

BioRender.com. We thank Kevin Kuang, Robert Fisher, and Noah Grunberg for their assistance in preparing this manuscript.

CONFLICT OF INTEREST

RMA and MW's interests were reviewed and are managed by the Boston University School of Medicine in accordance with their conflict of interest policies. The remaining authors state no conflict of interest.

AUTHOR CONTRIBUTIONS

Writing - Original Draft Preparation: AH, FG, SN, SR; Writing - Review and Editing: RMA, MW

References

Ahn A, Chatterjee A, Eccles MR. The slow cyclinG phenotype: a growing problem for treatment resistance in melanoma. Mol Cancer Ther 2017;16:1002–9.

Arozarena I, Wellbrock C. Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nat Rev Cancer 2019;19:377–91.

Arrowsmith CH, Boutrou C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012;11:384–400.

Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006;24:268–73.

Bajpe PK, Prahlad A, Horlings H, Nagtegaal D, Beijersbergen R, Bernards R. A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity. Oncogene 2015;34:531–6.

Bandyopadhyay D, Okan NA, Bales E, Nascimento L, Cole PA, Medrano EE. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res 2002;62:6231–9.

Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769–84.

Boumahdi S, de Sauvage FJ. The great escape: tumor cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov 2020;19:39–56.

Budden T, van der Westhuizen A, Bowden NA. Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma. BMC Cancer 2018;18:100.

Chatterjee A, Rodger EJ, Ahan A, Stockwell PA, Parry M, Motwani J, et al. Marked global DNA hypomethylation is associated with constitutive PD-L1 expression in melanoma. Science 2018;343:312–25.

Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses [published correction appears in Cell 2016;164:1073] [published correction appears in Cell 2017;169:361].

Cell 2015;162:974–86.

Chiappinelli KB, Zahnow CA, Ahuja N, Baylin SB. Combining epigenetic and immunotherapy to combat cancer. Cancer Res 2016;76:1683–9.

Christman JK. 5-azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21:5483–95.

Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012;150:12–27.

Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics 2009;1:239–59.

Emmons MF, Faião-Flores F, Sharma R, Thapa R, Messina JL, Becker JC, et al. HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRF1 inhibitor therapy. Cancer Res 2019;79:2947–61.

Emran AA, Chatterjee A, Rodger EJ, Tiffen JC, Gallagher SJ, Eccles MR, et al. Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy. Trends Immunol 2019;40:328–44.

Enninga EAL, Moser JC, Weaver AL, Markovic SN, Brewer JD, Leontovich AA, et al. Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011. Cancer Med 2017;6:2203–12.

Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143–53.

Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983;301:89–92.

Follanti E, Nicolay HJ, Sigalotti L, Calabro L, Pezzani L, Colizzi F, et al. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2’-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res 2007;13:3333–8.

Gallagher SJ, Gunatilake D, Beaumont KA, Sharp DM, Tiffen JC, Heinemann A, et al. HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. Int J Cancer 2018;142:1926–37.

Garcia-Peterson LM, Wilking-Busch MJ, Ndiaye MA, Philippe CGA, Setaluri V, Ahmed N. Sirtuins in skin and skin cancers. Skin Pharmacol Physiol 2017;30:216–24.

Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest 2018;128:3813–8.

Heinemann A, Cullinan C, De Padi-Heppi R, Wilmont JS, Gunatilake D, Madore J, et al. Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. Oncotarget 2015;6:21507–21.

Héninger E, Krueger TE, Lang JM. Augmenting antimtumor immune responses with epigenetic modifying agents. Front Immunol 2015;6:29.

Holliday R. A new theory of carcinogenesis. Br J Cancer 1979;40:513–22.

Hornig E, Hepp MV, Graf SA, Ruzicka T, Berking C. Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside. Exp Dermatol 2016;25:831–8.

Hou P, Liu D, Dong J, Xing M. The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle 2012;11:2866–95.

Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, et al. p53 is regulated by the lysine demethylase LSD1. Nature 2007;449:105–8.

Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004;23:4225–31.

Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev 2003;2:415–28.

Jung H, Kim HS, Kim JY, Sun JM, Ahn JS, Ahn MJ, et al. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat Commun 2019;10:4278.

Kalin JH, Wu M, Gomez AV, Song Y, Das J, Hayward D, et al. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nat Commun 2018;9:53.

Kampilafkos P, Melachrinou M, Kefalopontou Z, Lakoumentas J, Sotirou-Opoulou-Bonikou G. Epigenetic modifications in cutaneous malignant melanoma: EZH2, H3K4me2, and H3K27me3 immunohistochemical expression is enhanced at the invasion front of the tumor. Am J Dermatopathol 2015;37:138–44.

Khan AN, Gregorie CJ, Tomasbi TB. Histone deacetylase inhibitors induce TAP, LMP, tapasin genes and MHC class I antigen presentation by melanoma [published correction appears in Sci Rep 2019;9:14824]. Sci Rep 2019;9:6136.

Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med 2016;22:12834.

Koch T, Sahakian E, Banki D, Hadley M, Palmer E, Noonepalle S, et al. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells [published correction appears in Sci Rep 2019;9:14824]. Sci Rep 2019;9:6136.

Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, et al. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature 2017;530:128–32.

Laugesen A, Helin K. Chromatin repressive complexes in stem cells, development, and cancer. Cell Stem Cell 2014;14:735–51.
Epigenetic Therapies for Melanoma

A Hanly et al.

JID Innovations (2022), Volume 2